Lisa A Ridnour
Overview
Explore the profile of Lisa A Ridnour including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
3936
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ridnour L, Heinz W, Cheng R, Wink A, Kedei N, Pore M, et al.
Cancer Res Commun
. 2024 Oct;
4(10):2766-2782.
PMID: 39356141
This work identifies CD8-NOS2+COX2+ and CD8-NOS2-COX2+ unique cellular neighborhoods that drive the tumor immune spatial architecture of CD8+ T cells predictive of clinical outcome and can be targeted with clinically...
2.
Ridnour L, Cheng R, Kedei N, Somasundaram V, Bhattacharyya D, Basudhar D, et al.
JCI Insight
. 2024 Jun;
9(12).
PMID: 38912586
Immune therapy is the new frontier of cancer treatment. Therapeutic radiation is a known inducer of immune response and can be limited by immunosuppressive mediators including cyclooxygenase-2 (COX2) that is...
3.
Coutinho L, Femino E, Gonzalez A, Moffat R, Heinz W, Cheng R, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892290
Nitric oxide (NO) and reactive nitrogen species (RNS) exert profound biological impacts dictated by their chemistry. Understanding their spatial distribution is essential for deciphering their roles in diverse biological processes....
4.
Ridnour L, Cheng R, Heinz W, Pore M, Gonzalez A, Femino E, et al.
bioRxiv
. 2024 Jan;
PMID: 38187660
Multiple immunosuppressive mechanisms exist in the tumor microenvironment that drive poor outcomes and decrease treatment efficacy. The co-expression of NOS2 and COX2 is a strong predictor of poor prognosis in...
5.
Ridnour L, Heinz W, Cheng R, Wink A, Kedei N, Pore M, et al.
bioRxiv
. 2024 Jan;
PMID: 38187532
Estrogen receptor-negative (ER-) breast cancer is an aggressive breast cancer subtype with limited therapeutic options. Upregulated expression of both inducible nitric oxide synthase (NOS2) and cyclo-oxygenase (COX2) in breast tumors...
6.
Miranda K, Ridnour L, Cheng R, Wink D, Thomas D
Crit Rev Oncog
. 2023 Oct;
28(1):27-45.
PMID: 37824385
Nitric oxide (NO) and the enzyme that synthesizes it, nitric oxide synthase 2 (NOS2), have emerged as key players in inflammation and cancer. Expression of NOS2 in tumors has been...
7.
Cheng R, Ridnour L, Wink A, Gonzalez A, Femino E, Rittscher H, et al.
Cell Death Dis
. 2023 May;
14(5):319.
PMID: 37169743
A strong correlation between NOS2 and COX2 tumor expression and poor clinical outcomes in ER breast cancer has been established. However, the mechanisms of tumor induction of these enzymes are...
8.
Cheng R, Ridnour L, Wink A, Gonzalez A, Femino E, Rittscher H, et al.
bioRxiv
. 2023 Apr;
PMID: 37066331
A strong correlation between NOS2 and COX2 tumor expression and poor clinical outcomes in ER-breast cancer has been established. However, mechanisms of tumor induction of these enzymes are unclear. Analysis...
9.
Gouveia Junior F, Silveira J, Holanda T, Marinho A, Ridnour L, Wink D, et al.
Dalton Trans
. 2023 Mar;
52(16):5176-5191.
PMID: 36970749
Nitrosyl ruthenium complexes are promising platforms for nitric oxide (NO) and nitroxyl (HNO) release, which exert their therapeutic application. In this context, we developed two polypyridinic compounds with the general...
10.
Cheng R, Burkett S, Ambs S, Moody T, Wink D, Ridnour L
Biomolecules
. 2023 Feb;
13(2).
PMID: 36830680
The small endogenous signaling molecule nitric oxide (NO) has been linked with chronic inflammation and cancer. The effects of NO are both concentration and temporally dependent; under some conditions, NO...